FDA proposes adding bemotrizinol to U.S. sunscreens — a potential boost for consumers and coastal businesses
The FDA has proposed adding bemotrizinol to the U.S. sunscreen monograph, potentially the first new active ingredient in over 25 years, promising broad‑spectrum UVA/UVB protection and opening public comment before any final FDA rulemaking order.
Key takeaways
- Proposed addition: The FDA press announcement would add bemotrizinol to the U.S. sunscreen monograph if finalized.
- Usage limits: The proposal would allow bemotrizinol at up to 6% in lotions, creams, gels, sticks and certain sprays for adults and children 6 months and older, per legal summaries (AFS Law analysis; Holland & Knight analysis).
- Next steps: The agency has opened a public comment period and must complete federal rulemaking and issue a final order before bemotrizinol products can be marketed in the U.S. (FDA proposal).
What the FDA says and what it means
The agency characterizes bemotrizinol as a potent broad‑spectrum filter with a favorable safety profile: low skin absorption and infrequent irritation. That evidence underpins the agency’s view that the ingredient could be generally recognized as safe and effective (GRASE) if the rulemaking process is completed.
“We’re continuing to modernize the regulation of sunscreen and other over‑the‑counter drug products,” said FDA Commissioner Marty Makary in the FDA release.
Acting Office of Nonprescription Drugs director Karen Murry, MD, described bemotrizinol as “a welcome addition” and said the agency hopes to move more quickly on other active ingredients, per the same FDA material.
How bemotrizinol would be used
DSM Nutritional Products LLC requested the addition. The proposed rule would permit bemotrizinol in lotions, creams, gels, sticks and certain sprays at concentrations up to 6% for adults and children aged 6 months and older (AFS Law analysis; Holland & Knight analysis).
Bemotrizinol is already widely used in Europe and other markets as a broad‑spectrum UVA/UVB filter. International studies and regulatory reviews have generally supported its effectiveness and safety (scientific literature overview).
The difference between “proposed” and “approved”
A critical distinction: this is a proposed regulatory change. The FDA has opened a public comment period; only after completing federal rulemaking and issuing a final order can manufacturers legally market sunscreens containing bemotrizinol in the U.S. Some social posts mistakenly called the ingredient “approved” immediately after the announcement; the official notice clarifies the proposal status (FDA press announcement).
Market rollout and exclusivity
Industry reporting indicates bemotrizinol could be sold first under the trade name Parsol Shield by DSM, with a possible 2026 launch and an 18‑month exclusivity for DSM before others use the ingredient. Those commercial details come from DSM and Associated Press reporting and are not explicitly confirmed in the FDA proposal.
Regulatory and legal context
If finalized, bemotrizinol would be the first active ingredient added to the U.S. sunscreen monograph since 1999, according to legal analyses. That long interval has frustrated dermatologists, manufacturers and consumers who have sought filters available abroad (AFS Law analysis; Holland & Knight analysis).
Safety guidance from the FDA
The FDA emphasized that sunscreen is one part of sun safety. The agency continues to recommend broad‑spectrum sunscreens with SPF 15 or higher, protective clothing, hats and limiting time in direct midday sun. The proposal aims to expand consumer choice while reinforcing multi‑layered sun protection (FDA press announcement).
Implications for Huntington Beach, California
Economic impact
Huntington Beach’s economy—rooted in outdoor recreation, tourism and surf culture—could see modest local benefits if new, higher‑performance sunscreens reach market. Retailers, surf shops and hospitality businesses that sell sunscreens may update inventories and marketing to reflect consumer interest in advanced, low‑irritation filters.
Political consequences
Conservative audiences may welcome the FDA’s emphasis on regulatory modernization and consumer choice, while critics will likely seek clear timelines and safeguards against market concentration during any exclusivity period.
Social effects and cultural relevance
Improved sunscreen options could lower sunburn rates and long‑term skin cancer risk for residents and visitors who adopt them. Surf and beach culture values performance and comfort; new filters marketed to athletes and surfers could resonate strongly.
Practical applications for residents
- Retailers: Monitor the FDA docket and industry notices to prepare for product launches and labeling changes.
- Lifeguards and schools: Coordinate with county health officials about sunscreen supplies used in programs and public events.
- Consumers: Continue to follow established sun safety—broad‑spectrum SPF 15+, reapplication, protective clothing and limiting midday sun exposure—until products become available.
Sources and further reading
- FDA press announcement
- AFS Law analysis: “FDA proposes first new sunscreen active ingredient in two decades”
- Holland & Knight analysis: “FDA proposes first new sunscreen ingredient in decades”
- Scientific literature overview of bemotrizinol
Public comment and next steps
The FDA’s notice opens a docket for public comment. Stakeholders—including consumers, medical professionals, manufacturers and local governments—can submit data or opinions before the agency issues a final order. Only after that administrative step can bemotrizinol‑containing sunscreens be marketed in the United States. For now, Huntington Beach residents and businesses should watch for updates from the FDA and industry announcements before changing procurement or usage policies.
